Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited in competition
WADA 2026: S6.A, non-specified, prohibited in competition. The future 2027 List retains this classification. [1] [2]
2026 and 2027 List, S6.A, printed pp.15–16; introductory definitions p.3 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Modern clinical use
Fenfluramine is the active drug in Fintepla. Reviewed US and EU information describes treatment of seizures associated with Dravet syndrome or Lennox–Gastaut syndrome in patients aged two years and older; EU use is add-on therapy. [3] [4]
- An epilepsy indication does not remove S6.A status.
Cardiac and pulmonary risks
Fintepla labeling warns about heart-valve disease and pulmonary arterial hypertension and requires specialist cardiac assessment. The patient population and monitored medicinal formulation matter when interpreting clinical evidence. [3] [4]
- No safety comparison with unrelated stimulants is established here.
What remains uncertain
- Educational synthesis only; not individualized medical advice, a TUE decision or a sanction prediction.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
Introduction p.3 · S6 pp.15–16
- WADA 2027 Prohibited List, 4 November revision ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected · FUTURE 2027 SOURCE
Introduction p.3 · S6 pp.15–16
- M10. EMA and DailyMed. Fintepla/fenfluramine medicine and cardiac/pulmonary warnings. ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
Boxed warning; section 5 · Clinical pharmacology 12.1 · Indications
- M10. EMA and DailyMed. Fintepla/fenfluramine medicine and cardiac/pulmonary warnings. ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
Boxed warning; section 5 · Clinical pharmacology 12.1 · Indications
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.